Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hemispherx BioPharma, Inc (HEB) Spikes On Extension Of Rintatolimod European EAP To Pancreatic Cancer

Shares of Hemispherx BioPharma, Inc (NYSEMKT:HEB) gained more than 12.75% in the last three days of the week, after the company announced its rintatolimod European early access program (EAP) had been extended to pancreatic cancer patients. The comprehensive program will first be open in the Netherlands.

Originally, Hemispherx BioPharma, Inc (NYSEMKT:HEB)’s rintatolimod EAP was designed to provide myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) patients with access to the compound, which recently obtained approval in Argentina, becoming the first in the world approved to treat ME/CFS.

people, person, lab, nuclear, hydrogen, concept, chemistry, technicians, researching, formula, chemists, biotechnology, researchers, discovery, weapon, samples,

Syda Productions/

The first patient for the pancreatic cancer EAP has already been dosed. A number of additional patients are in the queue to receive the rintatolimod therapy.

“Pancreatic cancer patients generally have a poor prognosis and few therapeutic options,” Hemispherx BioPharma, Inc (NYSEMKT:HEB) CEO Thomas Equels commented. “The cancer is commonly diagnosed at an advanced stage with a five-year survival rate of roughly only seven percent for all pancreatic cancer patients. We are happy to be able to expand our EAP to a patient population for this devastating malignancy with such a clearly unmet medical need.”

Follow Aim Immunotech Inc. (NYSEMKT:AIM)
Trade (NYSEMKT:AIM) Now!

Disclosures: The author holds no interest in any of the securities or entities mentioned above. He has not received compensation for this article, other than from Small Cap Nation. The statements above do not constitute recommendations. The article has been based on publicly available information, and seeks to be unbiased and non-promotional.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.